<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072746</url>
  </required_header>
  <id_info>
    <org_study_id>OICB10007</org_study_id>
    <secondary_id>K23AA018399</secondary_id>
    <nct_id>NCT02072746</nct_id>
  </id_info>
  <brief_title>Zinc Supplementation in Alcoholic Cirrhosis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if zinc therapy: (1) strengthens your intestine's&#xD;
      defensive barrier preventing damaging substances from reaching your liver, (2) decreases&#xD;
      liver injury (inflammation, oxidative stress, cell death) and scarring, and (3) improves your&#xD;
      liver-related health. Based on our preliminary animal data and other published reports, we&#xD;
      expect zinc therapy to achieve all of these goals. Zinc is affordable, available over the&#xD;
      counter or by prescription, and has an excellent safety profile. Positive results from this&#xD;
      study will show that zinc is a significant therapy for millions of Americans with alcoholic&#xD;
      liver disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-thirds of Americans consume alcohol, and an estimated 14 million Americans are&#xD;
      alcoholics. It has been estimated that 15%-30% of heavy drinkers develop advanced Alcoholic&#xD;
      liver disease (ALD). The prevalence of ALD in the United States is conservatively estimated&#xD;
      at 2 million persons. Nearly 50% of liver-related deaths and 30% of hepatocellular carcinomas&#xD;
      in the US are due to alcoholic cirrhosis. Despite recent advances in our understanding of&#xD;
      ALD, there is currently no FDA approved medication for any stage of ALD. Zinc sulfate is&#xD;
      inexpensive, available over the counter, and has an excellent safety profile. If zinc&#xD;
      positively influences the mechanisms postulated to play a role in human ALD, this affordable&#xD;
      treatment would become relevant to millions of people worldwide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Actual">March 1, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in clinical status</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Whether the subject has improved clinically at time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood zinc levels</measure>
    <time_frame>0,3,6,12,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum endotoxin levels</measure>
    <time_frame>0,3,6,12,24 months</time_frame>
    <description>Whether the subject has a change in the serum endotoxin levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Alcoholic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Zinc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zinc sulfate 220 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo study for comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <arm_group_label>Zinc</arm_group_label>
    <other_name>Zinc sulfate 220 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide informed consent.&#xD;
&#xD;
          2. Clinical diagnosis of alcoholic cirrhosis.&#xD;
&#xD;
          3. Between the ages of 18 years and 70 years.&#xD;
&#xD;
          4. Ability to attend all clinic visits and participate in monthly telephone calls.&#xD;
&#xD;
          5. Child-Pugh score of A or B.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy or intolerance to zinc sulfate.&#xD;
&#xD;
          2. Hospitalization within the previous 28 days.&#xD;
&#xD;
          3. Pregnancy.&#xD;
&#xD;
          4. Illicit drug use within the past 12 months.&#xD;
&#xD;
          5. Infection with hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          6. Known or suspected cancer within the past 5 years.&#xD;
&#xD;
          7. Serum creatinine greater than 1.5 mg/dl within the past month.&#xD;
&#xD;
          8. Any severe chronic disease other than liver disease.&#xD;
&#xD;
          9. Impairment (slowness) of behavior, intelligence, and neuromuscular function which may&#xD;
             indicate hepatic encephalopathy (slow or confused thinking due to your liver disease).&#xD;
&#xD;
         10. Participation in another clinical trial.&#xD;
&#xD;
         11. Any type of infection within the past month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Cave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Matthew Cave</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>alcohol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Alcoholic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

